Season 10 · Episode 35
S10 Ep35: Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations
OncLive® On Air · OncLive® On Air
June 6, 202413m 54s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Paik discusses key findings from the phase 2 VISION trial investigating frontline tepotinib in patients with NSCLC harboring MET exon 14 skipping alterations, real-world data from the TOGETHER pooled analysis of tepotinib vs other frontline treatment options in this patient population, and insights regarding treatment sequencing with tepotinib in pretreated patients in this population.